Purpose To investigate the prognostic value of whole-body magnetic resonance imaging (WB-MRI) for patients with multiple myeloma (MM).Materials and Methods Sixty-two newly diagnosed patients with MM confirmed by pathology during January 2010 and December 2016 were enrolled in this study.The patients were divided into five groups according to the infiltrative patterns on MRI:normal pattern,micro-nodular pattern,macronodular pattern,mixed pattern and diffuse pattern,and their overall survival were compared.Results Of all the patients,micro-nodular infiltrative pattern was found in 20 patients,macro-nodular pattern in 13 patients,mixed pattern in 7 patients and diffuse pattern in 17 patients,while 5 patients were normal.During the follow-up for a median of 39 months (ranged 30.9-47.1 months),overall survival with the mixed MM infiltrative pattern (median 17 months,95％ CI 12.6-21.3 months) was statistically shorter than those with other patterns (median 43 months,95％ CI 33.7-52.3 months;P＜0.05).Additionally,the clinical DurieSalmon (DS) and International Staging System (ISS) were applied to evaluate the stage of MM patients.DS system showed that 6 patients were at stage I,another 6 patients were at stage Ⅱ and the other 50 patients were at stage Ⅲ.While based on ISS system,15 patients were found at stage Ⅰ,22 patients were at stage Ⅱ and the rest 25 patients were at stage Ⅲ.Meanwhile,the correlation between the WB-MRI infiltrative pattems and DS system as well as ISS system had no significant correlation (P＞0.05).Conclusion Different infiltrative patterns in WB-MRI can predict the prognosis in patients with MM at the time of diagnosis.

Depression is one of the common and serious complications after stroke. Post-stroke depression (PSD) is associated with poor outcomes and increased mortality. The American Heart Association/American Stroke Association guidelines for the early management of patients with acute ischemic stroke recommend that pharmacological therapy should be administered to patients with PSD. This article reviews the pharmacological therapy for PSD.

Continuous renal replacement therapy (CRRT) has become an effective multiple organ support therapy instead of single renal replacement as initially expected, and it is widely used in intensive care unit (ICU). After the outbreak of coronavirus disease 2019 (COVID-19), a series of expert recommendation or consensus have been developed to diagnose and treat the disease, including CRRT in acute kidney injury (AKI) and hyper inflammatory response. However, CRRT in COVID-19 is extraordinarily different from regular one due to different pathophysiology and infectious clinical scenarios. Accordingly, the paper aims to elaborate the similarities and differences between CRRT in COVID-19 and routine treatment in terms of safety and accessibility, indications and timing, clinical operation, anticoagulation, fluid management, prevention and control of infectious diseases, etc.